Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.06.028
Abstract: OBJECTIVES Despite the scant docetaxel's tolerability, second-line association with nintedanib still represents a standard-of-care for non-squamous non-small cell lung cancer (nsNSCLC), giving to rapidly-progressing patients the greatest survival advantage. The SENECA trial is a phase… read more here.
Keywords: second line; nintedanib; lung cancer; line ... See more keywords
Nintedanib attenuates peritoneal fibrosis by inhibiting mesothelial‐to‐mesenchymal transition, inflammation and angiogenesis
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Cellular and Molecular Medicine"
DOI: 10.1111/jcmm.16518
Abstract: Nintedanib, an Food and Drug Administration (FDA) approved multiple tyrosine kinase inhibitor, exhibits an anti‐fibrotic effect in lung and kidneys. Its effect on peritoneal fibrosis remains unexplored. In this study, we found that nintedanib administration… read more here.
Keywords: peritoneal fibrosis; fibrosis; nintedanib; growth factor ... See more keywords
Effects of Nintedanib in an Animal Model of Liver Fibrosis
Sign Up to like & getrecommendations! Published in 2020 at "BioMed Research International"
DOI: 10.1155/2020/3867198
Abstract: Systemic sclerosis can affect multiple internal organs, including the liver and lungs. Nintedanib, an antifibrotic approved for treatment of interstitial lung disease associated with systemic sclerosis, may have activity outside of the lungs. This study… read more here.
Keywords: fibrosis; nintedanib; treatment; significantly reduced ... See more keywords
Anti-Fibrotic Drug Nintedanib Inhibits CSF1R to Promote IL-4-associated Tissue Repair Macrophages.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of respiratory cell and molecular biology"
DOI: 10.1165/rcmb.2022-0021oc
Abstract: Pro-fibrotic and pro-homeostatic macrophage phenotypes remain ill-defined, both in vivo and in vitro impeding successful development of drugs that reprogram macrophages as an attractive therapeutic approach to manage fibrotic disease. The goal to of this… read more here.
Keywords: macrophage phenotypes; tissue repair; nintedanib; anti fibrotic ... See more keywords
Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13164168
Abstract: Simple Summary Nintedanib is an anti-angiogenic agent that has received approval in the European Union for the treatment of non-small cell lung cancer (NSCLC) after first-line chemotherapy. Here, we explore the possibility that the flavonolignan… read more here.
Keywords: silibinin; nintedanib; cell; lung cancer ... See more keywords